RxDoctor Payments Data

Michael Monahan, DO

Urology · Albany, GANPI 1114213428

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $15,883 of the $18,175 with a category attached, or 87.4%. It is spread thinly across 39 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations.

$18,175in general payments, 2019–2025

Across 621 payments — averaging $29.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Axonics, Inc.$3K
  • Astellas Pharma US Inc$998
  • Sumitomo Pharma America, Inc.$939
  • Pfizer$881
  • Dendreon Pharmaceuticals LLC$845
  • plus $8K from 33 others

What the payments were for

  • Travel & lodging$2,13412%
  • Food & beverage$15,88387%
  • Education$1581%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,175 in reported general payments places this provider in the 85th percentile of 369 urology providers in Georgia.

See all urology providers in Georgia

Medicare billing

Part B allowed, 2024
$972,929
Medicare patients
1,434
Services billed
36,290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide70$909,958
OrgovyxRelugolix255$668,751
MyrbetriqMirabegron106$62,984
GemtesaVibegron96$58,141
Tamsulosin Hcl639$8,214
Finasteride251$2,835
Testosterone Cypionate64$1,636
Oxybutynin Chloride ErOxybutynin Chloride96$1,452
Estradiol19$1,238
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst53$1,195
Dutasteride29$1,082
Silodosin12$873
Cephalexin205$855
Desmopressin Acetate11$840
Ciprofloxacin Hcl128$495

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$998$972,942176 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$939$726,892351 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 369 urology providers in Georgia.

Other urology in Albany

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →